Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Inclusion Criteria * Subject is receiving the HM II per standard of care (SOC) in accordance with the FDA approved indications for use * Subject is ≥ 50 years of age * Subject is receiving the HM II as their first LVAD * Subject or legally authorized representative (LAR) has signed an informed consent form (ICF). Exclusion Criteria * Existence of ongoing mechanical circulatory support (MCS) other than intra-aortic balloon pump or Impella® devices * Participation in any other clinical investigation(s) involving an MCS device, or an investigation(s) that is likely to confound study results or affect study outcome * Antiplatelet therapy is mandated for other conditions, in particular: a) recent coronary artery stenting (≤ 6 months), b) carotid artery disease, and c) other conditions where the investigator is not comfortable leaving subjects off-ASA or starting ASA post LVAD implantation. In situations where the investigator is uncertain, the Steering Committee can provide recommendation to the investigator as needed. * Subjects in whom heart transplantation is expected in ≤ 6 months * Subjects with a known ASA allergy